JasonMHafronMDru
Urology • West Bloomfield, MIMinimally Invasive Surgery, Surgical Oncology
Professor of Urology at the William Beaumont School of Medicine Chief Medical Officer Director of Clinical Research Michigan Instiute of Urologyiii
Dr. Hafron is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6900 Orchard Lake Rd
Ste 101
West Bloomfield, MI 48322Phone+1 248-539-9036Fax+1 248-539-9267
Summary
- Dr. Jason Hafron is an urologist in West Bloomfield, MI and is affiliated with multiple hospitals in the area, including Beaumont Hospital - Royal Oak and Beaumont Hospital - Troy. He received his medical degree from Loyola University Chicago Stritch School of Medicine and has been in practice 17 years. He specializes in minimally invasive surgery and surgical oncology and is experienced in small cell carcinoma of the kidney, prostate cancer, gynecologic oncology, urologic oncology, and minimally invasive urologic surgery.
Education & Training
Cleveland Clinic FoundationFellowship, Minimally Invasive Urologic Surgery, 2007
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Urology, 2002 - 2006- Montefiore Medical Center/Albert Einstein College of MedicineResidency, Surgery, 2001 - 2002
Loyola University Chicago Stritch School of MedicineClass of 2000
Certifications & Licensure
MI State Medical License 2007 - 2026
OH State Medical License 2006 - 2008
NY State Medical License 2002 - 2004- American Board of Urology Urology
Clinical Trials
- A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma Start of enrollment: 2009 Sep 01
- S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
- Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer Start of enrollment: 2012 May 01
- Join now to see all
Publications & Presentations
PubMed
- Does size matter? A single institution's comparison of Aquablation in prostates greater than or less than 150 mL.Renee Ringler, David Gangwish, Paul Horning, Joshua Kuperus, Greg Palmateer
The Prostate. 2025-02-01 - Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing.Sophia M Abusamra, Marissa A Solorzano, Jake Quarles, Mallory Luke, Milan Patel
Urology Practice. 2025-01-01 - Patient reported health related quality of life outcomes after viable cryopreserved umbilical tissue placement directly over spared neurovascular bundles after robotic...Aidan Kennedy, Mit Shah, Alex Geisenhoff, Samantha Kraemer, Chirag Dave
Journal of Robotic Surgery. 2024-11-25
Journal Articles
- Twelve-Month Prostate Volume Reduction After MRI-Guided Transurethral Ultrasound Ablation of the ProstateJason Hafron, MD, European Radiology
Press Mentions
Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological AssociationMarch 16th, 2023- Variation and Correlation in Postoperative Imaging After Shockwave Lithotripsy and Ureteroscopy by Treatment Modality: Results of a Statewide Clinical RegistryOctober 1st, 2022
- IsoPSA Shows Notable Diagnostic Accuracy in Detecting Prostate CancerJuly 20th, 2022
- Join now to see all
Professional Memberships
- Member
- LUGPAMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
